Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004089 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer
A Phase 2 study of Head and Neck Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Study locations
NCT00004089: Completed Phase 2 study of Head and Neck Cancer, sponsored by National Cancer Institute (NCI).
NCT00004089 is a Phase 2 study of Head and Neck Cancer that has completed, run by National Cancer Institute (NCI). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004089, a Phase 2 study of Head and Neck Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating patients who have previously untreated anaplastic thyroid cancer.
Conditions Studied
Interventions
- DRUG paclitaxel
- DRUG fluorouracil
- PROCEDURE conventional surgery
- BIOLOGICAL filgrastim
- DRUG hydroxyurea
Study Locations (3)
Illinois
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Chicago
- University of Illinois at Chicago - Chicago
- University of Chicago Cancer Research Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-08 |
| Est. Completion | 2002-04 |
| Phase | Phase 2 |
What the finished NCT00004089 record still lists
NCT00004089 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 5 interventions - of which paclitaxel is the first listed.
NCT00004089 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00004089 about?
NCT00004089 is a clinical study titled "Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effe...
What is the current status of trial NCT00004089?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-08. Estimated completion is 2002-04.
What conditions does trial NCT00004089 study?
This clinical trial studies the following conditions: Head and Neck Cancer.
What interventions are being tested in trial NCT00004089?
The interventions under investigation include: paclitaxel (DRUG), fluorouracil (DRUG), conventional surgery (PROCEDURE), filgrastim (BIOLOGICAL), hydroxyurea (DRUG).
Who is sponsoring clinical trial NCT00004089?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004089 being conducted?
This trial has 3 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
-
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia